Schering Eulexin (flutamide) receives approval for use in early prostate cancer.

SCHERING EULEXIN EARLY-STAGE PROSTATE CANCER INDICATION CLEARS FDA June 21. Eulexin (flutamide) capsules are now "indicated for use in combination with LHRH agonists for the management of locally confined stage B2-C" prostate cancer, along with the previous indication for stage D2 metastatic carcinoma of the prostate. Labeling recommends that for stage B2-C, "treatment with Eulexin and the LHRH agonist should start eight weeks prior to initiating radiation therapy and continue during radiation therapy." Recommended dosing is the same for both indications: two 125 mg caps three times daily.